Accretion Nutraveda IPO

About Accretion Nutraveda IPO

The Accretion Nutraveda IPO opens on Wednesday, Jan 28, 2026 and closes on Friday, Jan 30, 2026. The allotment of shares will take place on Monday, Feb 2, 2026. The credit of shares to the demat account will take place on Tuesday, Feb 3, 2026. The initiation of refunds will take place on Tuesday, Feb 3, 2026. The listing of shares will take place on Wednesday, Feb 4, 2026.

The IPO of Accretion Nutraveda consists of a fresh issue. The fresh issue will include up to 0.19 crore shares of ₹24.77 crores. The total number of shares are 19,20,000 shares, aggregating up to ₹25 crores.

Accretion Nutraveda IPO price band is set at ₹122 to ₹129 per share. The lot size for an application is 1,000. The minimum amount of investment required by an individual investor (retail) is ₹2,58,000 (2,000 shares) (based on upper price). The minimum lot size required for investment by HNIs is 3 lots (3,000 shares), amounting to ₹3,87,000.

The company is in the business of the manufacturing of Ayurvedic and Nutraceutical products across several dosage forms, including Tablets, Capsules, Oral liquids, Oral Powders, External Preparation and Oils. They are a healthcare focused company specialising in contract manufacturing, serving domestic as well as export markets in various countries like Sri Lanka, Singapore and the USA.

Objectives of Accretion Nutraveda IPO

• Purchase of machinery for automation in the existing manufacturing unit.
• Purchase of machinery for new manufacturing setup.
• Funding working capital requirements of the company.
• General corporate purposes.

Industry Outlook

The Indian pharmaceutical sector is expected to grow at a CAGR of 22.4% in the near future. The government has set ambitious targets to boost the medical devices industry in India, aiming to elevate it from its current US$ 1100 crores valuation to US$ 5000 crores by 2030. India’s drugs and pharmaceuticals exports stood at Rs. 2,59,658 crore (US$ 3038 crores) in FY25 and Rs. 2,43,119 crore (US$ 2782 crores) in FY24. According to a recent EY-FICCI report, as there has been a growing consensus over providing new innovative therapies to patients, the Indian pharmaceutical market is estimated to touch US$ 13000 crores in value by the end of 2030 and US$ 45000 crores by 2047. India ranks third worldwide for pharmaceutical production by volume and 14th by value. The country has an established domestic pharmaceutical industry, with a strong network of 3,000 drug companies and ~10,500 manufacturing units.

Accretion Nutravda Company Information

Accretion Nutraveda offers a diverse range of dosage forms, leveraging both Classical Ayurvedic principles and modern nutraceutical science. Since its inception in 2021, the company has established itself as a reliable Contract Development and Manufacturing Organization (CDMO), offering specialized services to a wide range of clients across various industries.

Their product portfolio includes Tablets, such as film-coated and chewable varieties, for applications in liver care, gynecological care, bone and joint health, and respiratory support. They also manufacture Capsules, including hard gelatin and HPMC capsules, targeting areas like liver detoxification, women’s health, and cognitive support. Their oral liquids include syrups, suspensions, and tonics, which are particularly suited for paediatric and geriatric segments. Additionally, they produce traditional ayurvedic powders known as churans for digestive health, medicated ayurvedic oils for musculoskeletal and dermatological applications using traditional processes, and a range of external preparations like balms, ointments, creams, and gels for pain relief, skin care, and hair care. Their business operates through two primary verticals: Domestic Sales & Merchant Exports, which are conducted on a loan license basis, and Direct Exports.

Strengths of Accretion Nutraveda

• Experienced promoters and management team.
• Diverse product portfolio.
• Commitment to quality standards.
• Relationships with clients and suppliers.
• Business processes and management framework.

Risks of Accretion Nutraveda

• Dependency on a few customers for sales.
• A significant portion of their supply comes from their top 10 suppliers.
• High geographical concentration of their business (inability to expand beyond Gujarat and Maharashtra).
• Dependency on several third-party service providers to sell or distribute products, and on third party technology providers for certain aspects of operations.
• Require certain approvals and licenses in the ordinary course of business.

Notes:
A. All the financial information for Accretion Ayurveda above is sourced from the Restated Financial Statements dated December 29th 2025.
B. Considering the nature and size of business of the Company, the peer is not strictly comparable. However, the same have been included for broad comparison.
*Source: All the financial information for listed peer Company mentioned above is taken for the period as on September 30, 2025 (Half Yearly Unaudited result) available on the website of NSE dated December 22, 2025 to compute the corresponding financial ratios.
a. P/E ratios for the above peer company is based on closing market prices of equity shares on NSE dated December 22, 2025 divided by the Basic and Diluted EPS as at September 30, 2025
b. Basic and Diluted EPS refers to the Basic and Diluted EPS sourced from the available financial data as on September 30, 2025 of the listed peer company.
c. Return on Net Worth (%) for listed peer company has been computed based on the Net Profit After Tax for the period ended September 30, 2025 divided by Total Equity as on September 30, 2025.
d. NAV per share for listed peer company is computed as the net worth as on September 30, 2025 divided by the outstanding number of equity shares as on September 30, 2025.

Anchor Investor Bidding Date:

Tuesday, January 27, 2026 *

*The company, in consultation with the BRLM, may consider participation by Anchor Investors in accordance with the SEBI ICDR Regulations. The Anchor Investor Bid/ Issue Period shall be one Working Day prior to the Bid/ Issue Opening Date

• Registrar: KFin Technologies Limited
• Book Running Lead Managers: Sobhagya Capital Options Private Limited

Accretion Nutraveda Business Model

The company earns its revenue through manufacturing of Ayurvedic and Nutraceutical products across several dosage forms, including Tablets, Capsules, Oral liquids, Oral Powders, External Preparation and Oils. They specialise in contract manufacturing, serving domestic as well as export markets.

Accretion Nutraveda Growth Trajectory

The company’s Total Income grew to ₹16.055 crores in FY2025 from ₹5.197 crores in FY2024, and ₹3.071 crores in FY2023.

Their Profit After Tax increased to ₹2.613 crores in FY2025 from ₹0.822 crores in FY2024, and ₹0.281 crores in FY2023.

EBITDA also increased to ₹3.647 crores in FY2025 from ₹1.206 crores in FY2024, and ₹0.591 crores in FY2023.

Accretion Nutraveda Market Position

The domestic and merchant export vertical has been the dominant source of revenue, contributing 96.62% and 99.21% of their total revenue in FY 2024-25 and for the period ending September 30, 2025, respectively, while the direct exports vertical accounted for 3.38% and 0.79% of revenue, showing growth from previous years. Geographically, a significant majority of their revenue is generated within the state of Gujarat.

The company specializes in contract manufacturing and serves domestic and export markets, including countries such as Sri Lanka, Singapore, and the United States.

As of 31 March 2025, the company’s total income, profit after tax, and EBITDA were ₹16.055 crores, ₹2.613 crores, and ₹3.647 crores, respectively.

How to apply for Accretion Nutraveda IPO?

• Step 1: Log in to your Kotak Neo Demat account - Log in to your Demat account to access IPO investments. Next, select the current IPO section.
• Step 2: Specify IPO details - Enter the number of lots and the price you wish to apply for.
• Step 3: Enter UPI ID - After entering your UPI ID, click submit. This will place your bid with the exchange.
• Step 4: Mandate Notification - Your UPI app will receive a mandate notification to block funds.
• Step 5: Approve Request - Your funds will be blocked once you approve the mandate request on your UPI.